FAQ
Frequently Asked Questions
Straight answers to the questions people search most about these five compounds, each grounded in the cited research.
What is semaglutide?
Semaglutide is a synthetic peptide built on the structure of the natural gut hormone GLP-1 and engineered to remain active far longer than that native signal. It is an FDA-approved prescription medicine — not a supplement — with indications spanning type 2 diabetes, chronic weight management, cardiovascular risk reduction in certain adults, and the liver condition MASH.
What is semaglutide used for?
Its FDA-approved uses include type 2 diabetes management, chronic weight management in adults with obesity or overweight, reducing major cardiovascular events in certain adults with established heart disease, and treating metabolic dysfunction-associated steatohepatitis, or MASH. Approved formulations include an injection and an oral tablet.
How does semaglutide work?
It activates GLP-1 receptors throughout the body. In the pancreas, that boosts insulin release when blood sugar is high and suppresses glucagon, a hormone that raises blood sugar. It also slows how quickly food leaves the stomach, which blunts blood-sugar spikes after eating.
How does semaglutide work for weight loss?
The weight effect is mostly a brain effect. Semaglutide reaches appetite-control centers in the hypothalamus and brainstem, quieting the neural circuits that drive hunger and reinforcing the ones that signal fullness. In the landmark STEP 1 trial, that translated into an average 14.9% body-weight loss over 68 weeks, versus 2.4% with placebo [4].
What is tirzepatide?
Tirzepatide is a synthetic peptide that activates two hormone receptors at once — GIP and GLP-1 — making it the first approved "dual agonist" in this class. It's FDA-approved for type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity.
How does tirzepatide work?
It engages the GLP-1 receptor much the way semaglutide does — boosting insulin, suppressing glucagon, slowing gastric emptying — while adding a second signal through the GIP receptor. Lab studies show it's an imbalanced dual agonist, favoring GIP receptor engagement and a specific, biased pattern of GLP-1 receptor signaling, which researchers think contributes to its larger effect on weight [8].
What does tirzepatide do in the body?
By activating both GIP and GLP-1 receptors, it increases glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite through central brain circuits — producing larger effects on both blood sugar and body weight in trials than selective GLP-1 agonism alone.
What is tirzepatide used for?
Tirzepatide is FDA-approved for type 2 diabetes mellitus, chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity. In a 2025 head-to-head trial, it produced greater weight loss than semaglutide — 20.2% versus 13.7% over 72 weeks [1].
What is tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) — the signal the brain sends to the pituitary gland to release growth hormone. It doesn't add growth hormone directly; it amplifies the body's own release of it. It's FDA-approved for one specific use: reducing excess visceral fat in people with HIV-associated lipodystrophy.
What does tesamorelin do?
It binds GHRH receptors in the pituitary gland, stimulating the gland's normal, pulsatile release of growth hormone. That growth hormone prompts the liver to make more IGF-1, and together they promote fat breakdown with a notable preference for visceral fat — the fat around internal organs.
How does tesamorelin work?
Tesamorelin activates GHRH receptors on pituitary cells, triggering a signaling cascade (through the Gs/adenylyl-cyclase/cAMP pathway) that increases growth-hormone synthesis and release. Because it works by boosting the body's own natural GH pulses rather than supplying external growth hormone, its metabolic effects — especially on blood sugar — differ somewhat from giving recombinant growth hormone directly [15].
Will tesamorelin help me lose belly fat?
Tesamorelin is FDA-approved specifically to reduce visceral (deep abdominal) fat in people with HIV-associated lipodystrophy, and trials in that population show real, measured reductions — about 42 cm² more than placebo in the pivotal study [14]. It is not approved for general belly-fat reduction outside that specific condition, and visceral fat has been shown to reaccumulate within weeks of stopping treatment [16]. This is not a recommendation for any individual.
What does BPC-157 do in the body?
In animal and cell studies, BPC-157 promotes tissue repair, largely by encouraging the growth of new blood vessels (angiogenesis) through a pathway involving the VEGFR2 receptor. It has shown effects on healing gastric ulcers, tendons, and ischemic tissue in rodent models [20][21]. Human evidence for these effects is extremely limited — only three small pilot studies as of the most recent review [18].
Is BPC-157 a growth hormone?
No. BPC-157 is a pentadecapeptide derived from a gastric-juice protein fragment, structurally and functionally unrelated to growth hormone or GHRH analogues like tesamorelin. Its proposed mechanism centers on blood-vessel growth signaling, or angiogenesis, not the growth-hormone axis [20].
Does BPC-157 work immediately?
The published animal and pharmacokinetic data show BPC-157 clears the bloodstream quickly — an elimination half-life under 30 minutes in rat and dog studies [19] — but tissue-repair effects in animal models developed over days to weeks of repeated dosing, not immediately after a single dose. There is no controlled human trial measuring how quickly any reported effect appears in people.
Does BPC-157 damage the liver?
The published literature does not report liver damage from BPC-157; the first-in-human safety pilot found no measurable change in liver-related blood markers in the two participants tested [17]. That said, the human safety dataset is extremely small, and a 2025 review explicitly cautions that BPC-157 should be treated as investigational given how limited the human evidence remains [18].
What is PT-141?
PT-141, known by its drug name bremelanotide, is a synthetic cyclic peptide that activates melanocortin receptors in the brain, mainly MC4R. It's FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — a narrower approval than the compound's broader public discussion often implies.
What is PT-141 peptide?
It is a small cyclic peptide, structurally related to melanotan II but with a different chemical ending. It is an analogue of alpha-melanocyte-stimulating hormone, a natural signal involved in pigmentation and in central nervous-system pathways governing sexual desire.
What does the PT-141 peptide do?
It activates melanocortin receptors — chiefly MC4R — concentrated in brain regions like the hypothalamus and limbic system, engaging dopamine-linked circuits involved in sexual desire and arousal. This is a central, brain-based mechanism, unlike PDE-5 inhibitors, which act on blood vessels in the body.
What is PT-141 used for?
Its one FDA-approved use is acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, based on two identical Phase 3 trials in more than 1,200 women showing a statistically significant improvement in sexual desire [24]. Use in men or postmenopausal women is off-label and outside the studied, approved population.